Rhizen Pharmaceuticals AG Announces First Patient Dosing in a Phase II Study of Tenalisib (RP6530) in Locally Advanced or Metastatic Breast Cancer Patients

Rhizen Pharmaceuticals AG announced that it has commenced dosing in a Phase II trial to evaluate Tenalisib in patients with locally advanced or metastatic breast cancer.